These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18946069)

  • 1. Targeting EGFR in colorectal cancer.
    Messersmith WA; Ahnen DJ
    N Engl J Med; 2008 Oct; 359(17):1834-6. PubMed ID: 18946069
    [No Abstract]   [Full Text] [Related]  

  • 2. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 3. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab for metastatic colorectal cancer.
    Garattini S; Torri V; Floriani I
    N Engl J Med; 2009 Jul; 361(1):96; author reply 96-7. PubMed ID: 19579281
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-Ras mutations are changing practice in advanced colorectal cancer.
    McNeil C
    J Natl Cancer Inst; 2008 Dec; 100(23):1667-9. PubMed ID: 19033564
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
    Nozawa K; Watanabe T
    Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
    Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
    Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
    J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab for colorectal cancer.
    Roila F; Garassino MC; Mantica C
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340662
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
    Lien K; Berry S; Ko YJ; Chan KK
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab for colorectal cancer.
    Yang F; Fu D; Ni Q
    N Engl J Med; 2008 Mar; 358(11):1195; author reply 1196-7. PubMed ID: 18337611
    [No Abstract]   [Full Text] [Related]  

  • 18. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab for colorectal cancer.
    Fraggetta F; Pelosi G
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340663
    [No Abstract]   [Full Text] [Related]  

  • 20. Cetuximab for colorectal cancer.
    van der Spek E; Sonke GS
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.